Alert Done Done Edit In progress Play Run workshop Download Down Close All modules Educator In progress Learner How to Delete Information Credits Undo Time Left Right Right Down Locked Hide Home Menu Twitter LinkedIn icons.facebook Plus

Novel non-statin therapies in patients at high CV risk

Withdrawal from statins due to intolerance or poor adherence raises the risk of cardiovascular events in these patients. So what non-statin novel options are there for these patients? Join Prof. Alberico Catapano as he discusses some of the latest clinical data for various non-statin options that are known to reduce cholesterol and CV risk. Prof. Alberico Catapano is the Director of the Laboratory of Lipoproteins, Atherosclerosis and the Center for the Study of Atherosclerosis at Bassini Hospital, and at Multimedica IRCCS Milan, Italy.

Pre-Activity Information

Magnifying glass

Healthcare practitioners with an interest in lipid lowering and/or cardiovascular risk

Checklist

After completing this educational activity, learners will be able to 

  1. Interpret the safety and efficacy conclusions that can be drawn from currently available data for non-statin-based lipid-lowering therapies.
  2. Identify appropriate guideline-recommended lipid targets for patients with dyslipidemia.
Faculty

Faculty: Professor Alberico Catapano

Type of affiliation / financial interest Name of commercial company
Honoraria, lecture fees or research grants from: Aegerion, Akcea Therapeutics, Amarin, Amgen, Amryt Pharma, AstraZeneca, Daiichi Sankyo, Esperion, Ionis Pharmaceutical, Medscape Education, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sanofi, The Corpus, Viatris

Staff Disclosures

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. 

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Hand with money

This independent educational activity is supported by an educational grant from Daiichi Sankyo. The educational content has been developed by Liberum IME in collaboration with an independent faculty; Daiichi Sankyo had no influence on the content of this educational activity.

This module was accredited on the 23 August 2023 and will expire on the 23 August 2024.

The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.

ACHL accreditation statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the ACHL and Liberum IME. ACHL is accredited by the ACCME to provide continuing medical education for physicians. 

The Academy for Continued Healthcare Learning (ACHL) designates this enduring material for up to 0.25 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.

The American Medical Association (AMA) has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu

The content for this activity was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors. 

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Video

Accreditation Expired

Professor Alberico Catapano

Novel non-statin therapies in patients at high CV risk

Global

Prof. Alberico Catapano provides a top-line overview of some of the latest clinical data on novel non-statin therapies in patients at high cardiovascular risk.

Accreditation Expired

Professor Alberico Catapano

Nuove terapie non statiniche in pazienti ad alto rischio CV

Italy

Il Prof. Alberico Catapano fornisce una panoramica di alcuni dei più recenti dati clinici sulle nuove terapie non statiniche in pazienti ad alto rischio cardiovascolare.

Accreditation Expired

Professor Alberico Catapano

Neue Nicht-Statin-Therapien bei Patienten mit hohem CV-Risiko

Germany

Prof. Alberico Catapano gibt einen Überblick über die neuesten klinischen Daten zu neuartigen Nicht-Statin-Therapien bei Patienten mit hohem kardiovaskulärem Risiko.

Accreditation Expired

Professor Alberico Catapano

Nuevas terapias sin estatinas en pacientes con alto riesgo CV

Spain

El Prof. Alberico Catapano ofrece una visión general de algunos de los datos clínicos más recientes sobre nuevas terapias sin estatinas en pacientes con alto riesgo cardiovascular.